Clinical trials: Atorvastatin, completed
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Hypertension, Hypercholesterolemia
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension…
- Conditions
- Hypertension, Hypercholesterolemia, Angina Pectoris
- Trial name
- NCT01190007
- Testing
- Caduet
- Where
- 20 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
CKD-391 Pharmacokinetic Study Phase I
A randomized, open-label, 2-way crossover study to compare the pharmacokinetics and safety CKD-391 to coadministration Atorvastatin and Ezetimibe in health volunteers.
- Trial name
- NCT02501200
- Testing
- CKD-391, Atrovastatin and Ezetimibe combination therapy
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases
The Effect of Statin Medications on Muscle Performance (The STOMP Study)
Statins are a group of medications that are used to lower cholesterol levels. Although serious side effects are rare, some people taking statins experience muscle pain or weakness.
- Trial name
- STOMP (NCT00609063)
- Testing
- Atorvastatin
- Where
- 3 sites in United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Hartford Hospital
Dyslipidemia
To Investigate Blood Lipid Changes and Safety After Litorvazet® Tablets in Dyslipidemia Patients
This study aims to investigate the lipid-lowering effects and safety of administering Litorvazet tablets (ezetimibe/atorvastatin) over a 24-week period in patients with dyslipidemia scheduled to receive Litorvazet tablets in a…
- Trial name
- NCT06866509
- Testing
- Litorvazet Tablet 10/10mg, Litorvazet Tablet10/20mg, Litorvazet Tablet 10/40mg
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Angina, Stable
Acupuncture in Patients With Stable Angina Pectoris
This trail aims to evaluate the efficacy of acupoints on the specific meridian for chronic stable angina pectoris, compared with acupoints on the other meridian, sham acupoints and waiting-list.
- Trial name
- ASAP (NCT01686230)
- Testing
- acupuncture, Basic treatment
- Where
- China
- Volunteers
- 404 people, healthy volunteers welcome
- Sponsor
- Chengdu University of Traditional Chinese Medicine
Cardiovascular Diseases, Coronary Artery Disease
Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant…
- Trial name
- LIGHT (NCT00993915)
- Testing
- Atorvastatin
- Volunteers
- 687 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy Volunteers
Effects of Statins on the Pharmacokinetics for Midazolam in Healthy Volunteers
The purpose of this study is to investigate whether statins have any influence on cytochrome P450 (CYP) 3A4 enzyme activity using a probe drug midazolam.
- Trial name
- H-17-21 (NCT00716846)
- Testing
- simvastatin, atorvastatin, pitavastatin
- Where
- Japan
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Hamamatsu University
Dyslipidemia
12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia
- Trial name
- NCT00664859
- Testing
- LCP-AtorFen
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Veloxis Pharmaceuticals
Healthy Volunteers
Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin
Study to determine the potential pharmacokinetic interaction of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate and amlodipine as amlodipine besilate at steady state after a multiple oral administration and…
- Trial name
- NCT04245046
- Testing
- Candesartan, Amlodipine, Atorvastatin
- Where
- Jordan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Midas Pharma GmbH
Hyperlipidemia
Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias
- Trial name
- NCT00137462
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 59 sites in United States, Canada
- Volunteers
- 900 people
- Sponsor
- Pfizer
Hypertriglyceridemia
Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
The purpose of this study is to evaluate the efficacy and safety of Omacor (omega-3-acid ethyl esters) combined with atorvastatin for lowering non-high-density lipoprotein cholesterol (non-HDL-C) in hypertriglyceridemic subjects.
- Trial name
- NCT00435045
- Testing
- Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin, atorvastatin
- Volunteers
- 245 people
- Sponsor
- GlaxoSmithKline
Myocardial Infarction, Reperfusion Injury
Myocardial Infarction Size Reduction With Atorvastatin
The purpose of this study is to determine if oral atorvastatin administered just before percutaneous coronary angioplasty for acute myocardial infarction improves early and late heart function as compared to placebo.
- Trial name
- NCT00286312
- Testing
- Atorvastatin
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- R&D Cardiologie
Coronary Arteriosclerosis
This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.
This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy.
- Trial name
- NCT00380939
- Testing
- Atorvastatin, Pravastatin
- Where
- 36 sites in United States
- Volunteers
- 600 people
- Sponsor
- Pfizer
Ischemia Reperfusion Injury, Cardiovascular Disease
Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?
To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after ischemic exercise in the non-dominant forearm.
- Trial name
- NCT00441597
- Testing
- atorvastatin
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Renal Failure Chronic Requiring Hemodialysis, Metabolic Syndrome
Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients
Hyperlipidemia and atherosclerosis lead to cardiovascular diseases and are an indirect cause of increased death rate in the general population.
- Conditions
- Renal Failure Chronic Requiring Hemodialysis, Metabolic Syndrome, Diabetes Mellitus Type 2, Hyperlipidemia
- Trial name
- NCT01448174
- Testing
- Atorvastatin
- Where
- Poland
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Poznan University of Medical Sciences
Myocardial Infarction
Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI
The primary goal To assess the effect of atorvastatin in patients treated since the first 24-96 hours of the disease on the parameters of global and regional myocardial deformation in the infarcted area and the structural and…
- Trial name
- CONTRAST (NCT02590653)
- Testing
- Atorvastatin
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Penza State University
Healthy
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
This phase II, open-label research study was conducted in 129 healthy volunteers. Each subject will be given one initial oral dose of one of 7 FDA-approved medications (probe drugs), followed by a 7 day period where subjects…
- Trial name
- NCT00359281
- Testing
- atorvastatin, simvastatin, ezetimibe
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Aegerion Pharmaceuticals, Inc.
Dyslipidemias
Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study
To evaluate the percentage of Korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin…
- Trial name
- AT GOAL (NCT00540293)
- Testing
- Atorvastatin
- Where
- 20 sites in South Korea
- Volunteers
- 425 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Metabolic Syndrome
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
The purpose of this study is to compare the efficacy of treatment with rosuvastatin with atorvastatin in reducing Low density lipoprotein cholesterol over 6 weeks of treatment in subjects with metabolic syndrome.
- Trial name
- NCT00654485
- Testing
- Rosuvastatin, Atorvastatin
- Volunteers
- 940 people
- Sponsor
- AstraZeneca